Meanwhile, JP Morgan downgraded its Prime Medicine Inc [PRME] rating to a Neutral from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who decreased its forecast for the stock in mid May from “a Buy” to “a Neutral”. JMP Securities began covering PRME with “Mkt outperform” recommendation on December 10, 2024. H.C. Wainwright started covering the stock on May 20, 2024. It rated PRME as “a Buy”.
Price Performance Review of PRME
On Tuesday, Prime Medicine Inc [NASDAQ:PRME] saw its stock fall -11.99% to $1.17. Over the last five days, the stock has lost -7.48%. Prime Medicine Inc shares have fallen nearly -59.76% since the year began. Nevertheless, the stocks have fallen -83.31% over the past one year. While a 52-week high of $8.27 was reached on 01/06/25, a 52-week low of $1.12 was recorded on 05/20/25. SMA at 50 days reached $1.5891, while 200 days put it at $2.9788.
Levels Of Support And Resistance For PRME Stock
The 24-hour chart illustrates a support level at 1.0767, which if violated will result in even more drops to 0.9783. On the upside, there is a resistance level at 1.3067. A further resistance level may holdings at 1.4383. The Relative Strength Index (RSI) on the 14-day chart is 40.11, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0290, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.97%. Stochastics %K at 31.98% indicates the stock is a holding.
